Loading…
← CockpitCompetitor Analysis › VBSN.SW IVF HARTMANN Holding AGOpen in the cockpit ↗

IVF HARTMANN Holding AGVBSN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties
Momentum weak 24
Mkt cap
$352M
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$73,762
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+31.4 pp
WACC 5.0%
Hurdle
-11 pp
Req g minus delivered
Close · CHFCHF 125.00
1D+0.8%
1W+0.4%
1M+0.8%
3M-8.1%
6M-2.0%
YTD-12.6%
1Y-8.1%
ATR %1.5%
52w lowhigh16.7% off high

What IVF HARTMANN does

Employees: 316

IVF HARTMANN at a glance

Size IVF HARTMANN (VBSN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $352M, the 149th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 125.00 on 18 Nov 2026.

Performance Over six months the shares fell 2.0%, against -18.1% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 6.9% over the last twelve months (peer median +2.2%); the operating margin is 14.0% (peer median 6.4%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 4.6× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 31.4 points above its cost of capital (5.0% WACC).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026VBSN.SW 100Peer median 83
Six months, rebased to 100: IVF HARTMANN against the median of its 20 peers (local-currency closes).

IVF HARTMANN financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 170MCHF 162MCHF 159MCHF 148MCHF 151M
Revenue growth—+2%+7%-2%—
Gross profitCHF 55.4MCHF 52.9MCHF 54.1MCHF 45.0MCHF 43.9M
EBITDACHF 28.6MCHF 21.8MCHF 24.7MCHF 17.6MCHF 16.1M
Net incomeCHF 20.3MCHF 18.3MCHF 20.3MCHF 15.1MCHF 11.2M
Free cash flowCHF 23.3MCHF 17.7MCHF 18.2MCHF 31.8MCHF 15.5M
Capital expenditureCHF 3.36MCHF 3.97MCHF 2.58MCHF 2.42MCHF 2.71M
Total debtn/aCHF 1.39MCHF 1.30MCHF 1.34MCHF 931,000

Quarterly statements and history in the cockpit →

IVF HARTMANN competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%300653EMBCYDES6883381609SBSCVCLTN688273377740301502BWAY3005626748197A605186VBSN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. IVF HARTMANN is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×100×200×300653EMBCYDES1609CVCLTN688273377740BWAY30056267482041197A300753VBSN.SWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IVF HARTMANN is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%300653EMBC6883381609SBSCLTN688273377740301502BWAY3005622041688468300753VBSN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IVF HARTMANN is the large dot.

IVF HARTMANN competitors and peer comparison

How IVF HARTMANN compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IVF HARTMANN against its 20 peers (data as of 18 Nov 2026)
MeasureVBSN.SWPeer medianRank in peer set
1-month return+0.8%-10.9%4th highest of 21
6-month return-2.0%-18.1%6th highest of 20
Distance from 52-week high-16.7%-47.5%3rd highest of 21
Revenue growth (TTM)+6.9%+2.2%10th highest of 21
Operating margin14.0%6.4%7th highest of 21
EV / Sales1.1×4.6×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)-12.7%16.4%4th least demanding of 15
Growth delivered (Del g)-1.3%+0.2%5th lowest of 15
Hurdle (Req g minus delivered)-11.4 pp+9.8 pp3rd least demanding of 15
ROIC minus cost of capital+31.4 pp-3.3 pp2nd highest of 19
EV / EBITDA6.8×11.9×3rd cheapest of 11
Net debt / EBITDA-3.6×0.4×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%1.1×-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%5.4×18.4%+4.4%
Embecta EMBCUnited States$345M+99%-8%26%1.6×-19.9%-0.1%
YD Bio YDESUnited States$344M+7%+17%-883%571.2×n/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%1.4×-0.3%-0.7%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%4.2×35.3%+5.2%
BioNote 377740.KSSouth Korea$337M-14%+12%18%1.0×-15.0%-28.5%
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%4.9×34.3%+0.4%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%4.4×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%6.4×15.8%-4.5%
Shanghai General Healthy Information & Technology 605186.SSChina$379M-26%-11%5%7.8×n/an/a
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%6.9×20.0%-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%7.4×n/an/a

Questions

Which companies are IVF HARTMANN's closest peers?
The cockpit's peer set: Yantai Zhenghai Bio-Tech (300653.SZ), Embecta (EMBC), YD Bio (YDES), Beijing Succeeder Technology (688338.SS), Star Sports Medicine (1609.HK), Stratec (SBS.DE), CapsoVision (CV), COLTENE (CLTN.SW).
Is IVF HARTMANN expensive compared with its peers?
On ev / sales it trades at 1.1× against a peer median of 4.6×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has IVF HARTMANN stock performed?
Over six months to 18 Nov 2026 the shares returned -2.0% against -18.1% for the median peer; over one year -8.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.